Compare diabetes blood tests—including A1C, fasting glucose, oral glucose tolerance testing, insulin, and C-peptide—for screening, diagnostic support, and ongoing monitoring.
Diabetes blood tests are not interchangeable. In nonpregnant adults, A1C, fasting plasma glucose, and the two-hour plasma glucose value from a 75-gram oral glucose tolerance test can be used for screening and diagnostic support. A random plasma glucose result can meet a diagnostic criterion when it is at least 200 mg/dL and occurs with classic symptoms of hyperglycemia or a hyperglycemic crisis. Unless hyperglycemia is unequivocal, an abnormal result in the diabetes range generally needs prompt confirmation with a repeat of the same test or a second accepted diagnostic test.12
A1C estimates longer-term glycemic exposure, fasting glucose is a single fasting measurement, and an oral glucose tolerance test evaluates the response to a defined glucose load. Insulin and C-peptide answer different, more targeted questions about insulin secretion and physiology; neither replaces accepted glucose-based or A1C diagnostic criteria. Fructosamine, ketones, islet autoantibodies, urine albumin, creatinine-based estimated glomerular filtration rate, and lipids serve still other purposes.
Emergency warning: Do not wait for a self-ordered laboratory result if you have vomiting, abdominal pain, deep or rapid breathing, fruity-smelling breath, marked dehydration, confusion, severe weakness, or other signs of possible diabetic ketoacidosis or hyperglycemic crisis. Seek urgent medical care. Ketoacidosis can occur at lower-than-expected glucose concentrations in people taking an SGLT2 inhibitor.1112
For broader context, start with the complete guide to lab tests and blood work, then use the guide to reading laboratory results to understand reference intervals, flags, units, and trends. The direct-access laboratory testing guide explains how consumer-initiated testing fits alongside clinician-directed care.
| Decision | What to know | Practical implication |
|---|---|---|
| Screen, diagnose, or monitor? | Those are separate clinical purposes. | Choose the test for the question instead of treating every glycemia marker as equivalent. |
| Is fasting required? | A1C does not require fasting. Fasting plasma glucose does. An oral glucose tolerance test has a defined protocol. | Follow the specific preparation instructions for the selected test and collection site. |
| Could A1C be unreliable? | Red-cell lifespan, blood loss, transfusion, anemia, some hemoglobin variants, pregnancy, kidney failure, and certain therapies can change interpretation. | Investigate important mismatches between A1C and glucose instead of averaging them away.3 |
| Does one result establish diabetes? | Usually not when symptoms or unequivocal hyperglycemia are absent. | Arrange appropriate confirmation and clinical review.1 |
| Are there crisis symptoms? | Ketoacidosis and severe hyperglycemia are time-sensitive emergencies. | Seek urgent care rather than relying on routine outpatient testing.12 |
Glucose is the principal sugar circulating in blood. Insulin helps move glucose into cells and restrains glucose production by the liver. Prediabetes describes glycemia above the usual range but below diabetes thresholds; diabetes describes persistent hyperglycemia meeting established criteria. These categories predict risk, but one value does not describe the whole person, the cause of hyperglycemia, or the treatment plan.
A1C reports the percentage of hemoglobin with attached glucose and generally reflects roughly the prior two to three months, with recent weeks contributing more. Plasma glucose is a point-in-time measurement. An oral challenge exposes impaired glucose handling that may not appear in fasting results. C-peptide is released with endogenous insulin and can help estimate the body’s own insulin production. Autoantibodies can support classification of autoimmune diabetes. Kidney, lipid, and urine tests monitor risks that become especially important after diabetes is diagnosed.
Screening looks for prediabetes or type 2 diabetes before obvious symptoms appear. The U.S. Preventive Services Task Force recommends screening nonpregnant adults ages 35 to 70 who have overweight or obesity and referring people with prediabetes to effective preventive interventions. It identifies A1C, fasting plasma glucose, and oral glucose tolerance testing as accepted screening approaches.4 Other organizations may use broader risk-based criteria, so age, family history, prior gestational diabetes, polycystic ovary syndrome, cardiovascular risk, medications, and health disparities may change the right timing.
A value in the diabetes range requires context. In an asymptomatic person without unequivocal hyperglycemia, confirmation can be a repeat of the same test on a new sample or a different accepted diagnostic test. If two different tests disagree, clinicians generally repeat the test that is above the diagnostic threshold and investigate factors that could explain the mismatch.1
Monitoring asks whether a treatment plan is working and whether risk is changing. A1C is commonly checked about twice yearly when glycemia is stable and at goal, and about every three months when therapy has changed or goals are not being met; individual circumstances can require a different schedule.17 Continuous glucose monitoring and home glucose meters provide a different kind of information and should not be confused with laboratory diagnostic criteria.
Once hyperglycemia is established, the next question may be why it is occurring. C-peptide and islet autoantibodies can be useful when type 1 diabetes, type 2 diabetes, latent autoimmune diabetes in adults, monogenic diabetes, medication effects, or pancreatic disease overlap clinically. Kidney and cardiovascular testing addresses complications and risk; it does not re-diagnose diabetes.
| Test | Normal range | Prediabetes range | Diabetes criterion |
|---|---|---|---|
| A1C | Below 5.7% | 5.7% to 6.4% | 6.5% or higher |
| Fasting plasma glucose | 99 mg/dL or lower | 100 to 125 mg/dL | 126 mg/dL or higher |
| Two-hour plasma glucose during a 75-gram oral glucose tolerance test | 139 mg/dL or lower | 140 to 199 mg/dL | 200 mg/dL or higher |
| Random plasma glucose | No universal screening threshold in this table | 200 mg/dL or higher with classic hyperglycemia symptoms or hyperglycemic crisis | |
These are diagnostic cut points, not personalized treatment targets. The fasting measurement follows at least eight hours without caloric intake. The random criterion depends on symptoms or crisis. Pregnancy uses different screening strategies and thresholds. Without unequivocal hyperglycemia, confirmation is generally required.1214
The first tier is usually a purpose-selected A1C or plasma glucose measurement, not the largest available panel. The table distinguishes single tests, protocol-based testing, convenience panels, and pregnancy-specific products.
| Test and quick facts | What it shows and how it is used | Preparation, influences, and limitations |
|---|---|---|
| Standalone A1C test Longer-term glycemic exposure | Supports screening, diagnostic confirmation, and monitoring in appropriate patients. | Fasting is not required. Red-cell turnover, anemia, transfusion, some hemoglobin variants, pregnancy, kidney disease, and certain therapies can alter interpretation. |
| Fasting glucose blood test Single plasma glucose measurement | Supports screening and diagnostic confirmation when collected under fasting conditions. | Requires at least eight hours without caloric intake for a diagnostic fasting value. Acute illness, stress, medicines, and sample handling can influence the result. |
| Random glucose blood test No scheduled fast | Useful when symptoms are present. A result at or above 200 mg/dL meets a diagnostic criterion only with classic symptoms or hyperglycemic crisis. | Meal timing and acute stress matter. An isolated value without the required clinical context does not replace confirmation. |
| 75-gram two-specimen oral glucose tolerance test Fasting and two-hour specimens | Can detect impaired glucose tolerance and diabetes that fasting or A1C measurements miss. | Requires protocol-specific fasting, glucose ingestion, timing, and remaining at the collection site. Illness, activity, smoking, medicines, and preanalytic delay can affect results. |
| Hemoglobin A1C and glucose panel Two complementary glycemia markers | Compares a longer-term estimate with a point-in-time glucose measurement. | Confirm whether the glucose component is intended to be fasting. A panel does not remove the need for confirmation or interference review. |
| Hemoglobin A1C, insulin and glucose panel Adds an insulin measurement | May support a targeted metabolic trend discussion, but the insulin component is not an accepted stand-alone diabetes diagnostic criterion. | Fasting and medication context are essential. Insulin assays are not standardized well enough for universal diagnostic cutoffs. |
| Blood Sugar Test Panel Current page lists C-peptide, glucose, A1C, and insulin | Collects complementary markers for a broader physiologic view; each component answers a different question. | Do not treat the panel as one composite diagnosis. Reconfirm current contents and preparation instructions at the time of purchase. |
| Diabetes Monitoring Panel Convenience monitoring product | May combine glycemia and related-risk measures for established monitoring needs. | Confirm current components before purchase and use the individual results, clinical history, and treatment goals to guide interpretation. |
| Gestational glucose challenge with 135 mg/dL cutoff Pregnancy-specific product | Supports a clinician-selected gestational diabetes screening pathway. | Use only within the intended pregnancy protocol. A screening cutoff is not the same as a diagnosis. |
| Gestational glucose challenge with 140 mg/dL cutoff Pregnancy-specific product | Supports a different clinician-selected gestational diabetes screening threshold. | Do not choose between pregnancy protocols without prenatal guidance; follow the exact collection instructions. |
These tests refine a question; they do not replace core diagnostic criteria. Laboratory guidance advises against routine insulin or proinsulin testing for most people being evaluated for diabetes risk, and insulin results should not be added to an oral glucose tolerance test to diagnose diabetes. C-peptide is most useful when endogenous insulin production or diabetes classification is genuinely uncertain.5
| Test and quick facts | What it shows and how it is used | Preparation, influences, and limitations |
|---|---|---|
| Fructosamine blood test Roughly two to three weeks of glycemia | May help when A1C is unreliable or a shorter response interval is needed. | Protein turnover, albumin concentration, thyroid disease, liver disease, and kidney disease can affect interpretation. There are no universally standardized diabetes diagnostic thresholds. |
| 1,5-anhydroglucitol blood test Recent glycemic excursions | Can reflect glycemic control over approximately the preceding one to two weeks and may be used as a supplemental monitoring marker.10 | Not a diagnostic substitute. SGLT2 inhibitors and altered renal glucose handling can make the result unreliable. |
| Fasting insulin blood test Circulating insulin concentration | May support selected evaluations of hypoglycemia, endogenous hyperinsulinemia, or trend-oriented metabolic questions. | Routine use for diabetes diagnosis is not recommended. Results depend on glucose, fasting state, medication, kidney function, and a nonstandardized assay. |
| C-peptide blood test Endogenous insulin secretion | Can help distinguish low from preserved insulin production, classify difficult diabetes presentations, or investigate hypoglycemia. Injected insulin does not contain C-peptide.13 | Interpret with the concurrent glucose value, meal or stimulation state, kidney function, disease duration, and treatment. A single value is not a stand-alone type 1 or type 2 diagnosis. |
| Proinsulin blood test Insulin precursor | Reserved for specialist-directed endocrine questions, especially selected hypoglycemia evaluations. | Not recommended for routine diabetes screening or diagnosis; interpret with paired clinical and biochemical data. |
| Beta-hydroxybutyrate blood test Major circulating ketone body | Supports assessment and monitoring of ketosis or ketoacidosis in the proper clinical setting. | Routine outpatient ordering must never delay emergency care. Blood beta-hydroxybutyrate is more informative for ketoacidosis than urine ketones alone.5 |
| Serum osmolality blood test Concentration of dissolved particles | May contribute to clinician-directed evaluation of severe hyperglycemia, dehydration, or altered mental status. | Not a routine screening test. Suspected hyperosmolar crisis requires immediate clinical assessment and additional laboratory data. |
Classification tests are targeted tools for uncertain or atypical presentations, not a routine add-on for every person with hyperglycemia. Complication-monitoring tests answer a separate question: whether diabetes or related cardiometabolic risk is affecting kidneys, blood vessels, or other systems. Current standards use both urine albumin and estimated glomerular filtration rate to monitor kidney risk because the two measures provide complementary information.6
| Test and quick facts | What it shows and how it is used | Preparation, influences, and limitations |
|---|---|---|
| Type 1 diabetes autoantibody screening panel Multiple autoimmune markers | May support classification when autoimmune diabetes is suspected or when a clinician selects risk-based autoantibody screening. | Positive antibodies indicate autoimmunity, not current glycemic severity. Negative results do not exclude every form or stage of type 1 diabetes. |
| GAD65 antibody blood test Islet autoantibody | Often used in a targeted panel or staged evaluation when adult-onset autoimmune diabetes is possible. | Not a stand-alone population diabetes diagnosis. |
| IA-2 antibody blood test Islet autoantibody | Adds classification evidence when interpreted with other autoantibodies, glucose findings, and clinical history. | Sensitivity varies by disease stage and patient group; a result should not be interpreted in isolation. |
| Insulin autoantibody blood test Islet autoantibody | Can support autoimmune classification, particularly when measured before insulin therapy. | Injected insulin can lead to antibodies that complicate interpretation, so treatment history is essential. |
| Islet cell antibody screen with reflex to titer Indirect immunofluorescence approach | May add evidence in a targeted autoimmune diabetes evaluation. | Method and titer matter. Use with other markers rather than as a stand-alone diagnosis. |
| Zinc transporter 8 antibody blood test Islet autoantibody | Can identify autoimmune diabetes in some people whose other antibody results are negative. | Best used as part of an appropriate classification strategy; it does not measure current glycemic control. |
| Random urine albumin with creatinine test Kidney-damage marker | Supports calculation or reporting of the urine albumin-to-creatinine ratio, an early marker of diabetic kidney disease and cardiovascular risk. | Exercise, fever, infection, menstruation, marked hyperglycemia, and blood pressure can transiently raise urine albumin. Persistent elevation requires confirmation. |
| Serum creatinine blood test Used to estimate filtration | Contributes to estimated glomerular filtration rate for kidney-function monitoring and medication decisions. | Muscle mass, diet, hydration, acute illness, and some medicines influence creatinine. The estimate is not interchangeable with urine albumin. |
| Lipid panel Cholesterol fractions and triglycerides | Assesses cardiovascular risk and helps guide risk-reduction therapy in people with prediabetes or diabetes. | Does not diagnose diabetes. Fasting requirements depend on the purpose and clinician or laboratory instructions.7 |
| Triglycerides blood test Single lipid measure | Contributes to cardiometabolic risk assessment; very high concentrations can indicate pancreatitis risk. | Meals, alcohol, acute glycemia, and medications can affect results. It is not a diabetes diagnostic measurement. |
| Complete urinalysis Urine chemistry and microscopy | May detect glucose, ketones, protein, infection clues, or other urinary findings that shape follow-up. | Urine glucose depends on the renal threshold and does not replace plasma-based diagnosis. Urine ketones alone are insufficient to diagnose or monitor ketoacidosis. |
| Electrolyte panel Sodium, potassium, chloride, and carbon dioxide measures | Can provide metabolic context during illness, dehydration, or clinician-directed treatment monitoring. | Not a diabetes diagnostic panel. Severe abnormalities or symptoms require timely clinical assessment. |
| Comprehensive metabolic panel Glucose plus kidney, liver, protein, and electrolyte measures | Offers broad metabolic context when multiple organ systems or medicines need review. | The included glucose is still a point-in-time value, and the broad panel does not substitute for a purpose-selected diagnostic strategy. |
The following products are not routine diabetes diagnostic tests. They belong in the article only when a symptom, medicine, organ-risk question, or mismatch between A1C and glucose creates a reason to use them.
| Test and quick facts | What it shows and how it is used | Preparation, influences, and limitations |
|---|---|---|
| Serum albumin blood test Major circulating protein | May add nutritional, liver, kidney, or protein-turnover context and can affect interpretation of fructosamine. | Not a diabetes test; interpret with the clinical reason for testing. |
| Alkaline phosphatase blood test Liver and bone enzyme | Supports evaluation of selected liver, bile-duct, or bone questions. | Not specific to one organ and not a diabetes diagnostic test. |
| Alanine aminotransferase blood test Liver-cell injury marker | May support evaluation of metabolic liver disease or medicine-related liver injury. | Does not diagnose diabetes or determine liver fat by itself. |
| Aspartate aminotransferase blood test Liver and muscle enzyme | Provides context for liver or muscle injury when interpreted with other findings. | Not specific to diabetes or to the liver. |
| Total bilirubin blood test Red-cell and liver-processing marker | May support evaluation of jaundice, hemolysis, or liver and bile-duct conditions. | Not a diabetes diagnostic test and should be interpreted with related results. |
| Complete blood count with differential and platelets Blood-cell measures | May identify anemia or altered blood-cell patterns that help explain an unexpected A1C result. | Does not prove that A1C is inaccurate; the type and cause of a blood-cell abnormality matter. |
| Creatine kinase total blood test Muscle-injury enzyme | May be used for muscle symptoms or selected medication monitoring. | Exercise and muscle injury can raise the result. It does not diagnose diabetes. |
| Ferritin blood test Iron-storage marker with inflammatory behavior | May help investigate iron status when anemia is suspected or A1C and glucose disagree. | Inflammation, liver disease, and other conditions can raise ferritin independent of iron stores. |
| Iron and total iron-binding capacity panel Circulating iron and binding measures | Helps characterize iron availability in a targeted anemia or A1C-discordance evaluation. | Timing, supplements, meals, inflammation, and blood loss can influence the pattern; it is not a diabetes test. |
| Hemoglobinopathy evaluation Hemoglobin-variant assessment | May help when a variant is suspected and an A1C method or result could be affected. | Use based on history or laboratory evidence; it is not a routine diabetes screen. |
| Liver function panel Group of liver-associated analytes | May support assessment of metabolic liver disease, medicine safety, or another liver question. | Panel names and contents vary, and many included markers reflect injury rather than true function. |
| Vitamin B12 blood test Nutrient marker | May be appropriate with neuropathy symptoms, macrocytosis, dietary risk, or long-term metformin exposure. | Not a diabetes test. Interpret borderline results and symptoms clinically. |
A1C depends on both glycemia and the lifespan and characteristics of red blood cells. A result may be falsely low when red cells circulate for less time, such as after acute blood loss or with some hemolytic processes. It may be falsely high in some iron-deficiency states. Recent transfusion, erythropoietin therapy, hemodialysis, pregnancy, and some hemoglobin variants can also complicate interpretation. The direction and size of an effect are not universal.3
When A1C and plasma glucose do not fit each other, check the basics before assigning a label:
| Question | Usually starts with | Add only when justified |
|---|---|---|
| Am I at risk but without symptoms? | A1C or fasting plasma glucose; an oral challenge is an alternative. | Risk-based cardiovascular or kidney assessment, not routine insulin testing. |
| Did one result enter the diabetes range? | Prompt confirmation with the same accepted test or a second accepted test. | Interference evaluation when results conflict. |
| Is established treatment working? | A1C plus home or continuous glucose data when used. | Shorter-term markers if A1C is unreliable or a rapid treatment response must be assessed. |
| Is the diabetes type uncertain? | Clinical history, glucose pattern, and treatment course. | C-peptide with concurrent glucose and a purpose-selected islet autoantibody strategy. |
| Could there be an acute ketone emergency? | Immediate clinical assessment. | Blood ketones, electrolytes, acid-base testing, kidney function, and other emergency studies selected by the treating team. |
| What complication risk needs monitoring? | Urine albumin-to-creatinine ratio, estimated filtration, blood pressure, and cardiovascular risk assessment as appropriate. | Eye, foot, nerve, liver, or other evaluations based on the care plan.8 |
This framework deliberately separates a minimal core from targeted additions. More markers are not automatically more informative: every added result creates a possibility of preanalytic variation, false alarms, duplicate information, and follow-up cost.
| Testing pattern | Before collection | Record for interpretation |
|---|---|---|
| A1C alone | Fasting is not normally required. | Recent bleeding or transfusion, anemia, pregnancy, kidney failure, hemoglobin variants, and red-cell-altering therapy. |
| Fasting glucose or fasting insulin | Follow the product and collection-site fasting instructions; diagnostic fasting glucose uses at least eight hours without calories. | Last food or caloric drink, acute illness, unusual exercise, alcohol, smoking, and relevant medicines. |
| Oral glucose tolerance testing | Follow the exact diet, fasting, glucose-load, activity, and timed-collection protocol. | Vomiting, incomplete drink, delayed specimens, activity, smoking, acute illness, or medicines that could invalidate the protocol. |
| C-peptide or insulin during hypoglycemia evaluation | Use clinician-directed timing; an unsupervised fast can be unsafe. | Concurrent glucose, symptoms, meal or stimulation state, insulin or secretagogue exposure, and kidney function. |
| Urine albumin monitoring | Avoid collection during a known urinary infection or immediately after unusually vigorous exercise when practical. | Fever, menstruation, infection, exercise, blood pressure, and marked hyperglycemia. |
Do not stop prescribed medication or change diabetes treatment merely to prepare for a test unless the prescribing clinician gives explicit instructions. Biotin, steroids, diuretics, antipsychotics, immunosuppressants, and other medicines can affect selected assays or glycemia; provide a complete medication and supplement list.
The laboratory reference interval printed on a report is not automatically a diagnostic threshold or treatment goal. Use the Ulta guide to interpreting laboratory reports for a structured review of flags, reference intervals, units, and serial results.
Suppose an asymptomatic nonpregnant adult has an A1C of 6.6% and a fasting plasma glucose of 118 mg/dL. The A1C is in the diabetes range, while fasting glucose is in the prediabetes range. This is not a reason to average the numbers. It is a reason to confirm the abnormal diagnostic test promptly and review possible A1C interference. If a repeat A1C remains at or above 6.5% using an appropriate method, the repeated abnormal result can establish the diagnosis in the proper clinical setting. If repeat testing is lower, the clinician investigates the discordance and follows the person over time.1
Seek urgent medical evaluation for symptoms suggesting diabetic ketoacidosis or severe hyperglycemia, including persistent vomiting, abdominal pain, deep or rapid breathing, fruity breath, marked thirst and urination with worsening weakness, dehydration, confusion, fainting, or inability to keep fluids down. People with diabetes who are sick and have glucose at or above 250 mg/dL are commonly advised to check ketones according to their sick-day plan, but symptoms and clinical deterioration matter more than waiting for any one number.12
Pregnancy, childhood, suspected type 1 diabetes, recurrent hypoglycemia, and use of medicines that raise ketoacidosis risk require a lower threshold for clinician involvement. SGLT2-inhibitor-associated ketoacidosis may occur even when glucose is below the level many people associate with a crisis.11
Diabetes testing works best when it is connected to the organ systems and metabolic risks that influence prevention and long-term care.
| Health area | Why it connects | Guide |
|---|---|---|
| Heart and cardiovascular health | Diabetes changes cardiovascular-risk assessment and prevention priorities. | Heart health blood tests |
| Metabolic health and weight | Weight, insulin sensitivity, fatty liver risk, and glycemia often change together. | Metabolic health and weight-loss blood tests |
| Kidney health | Urine albumin and estimated filtration are complementary diabetes kidney-risk measures. | Kidney function tests |
| Liver health | Metabolic liver disease and medication monitoring may shape a diabetes care plan. | Liver function tests |
Ulta Lab Tests provides consumer access to selectable laboratory tests and panels, posted product pricing, collection through participating locations, and electronic result delivery as described on its current site. Test availability, eligibility, collection options, and state restrictions can vary. Product contents, preparation instructions, and prices can change, so review the current product page before purchasing.
Direct access is most useful when it supports a clear question, an appropriate testing interval, and a plan for abnormal or urgent results. It is not a substitute for emergency care, diagnosis by a qualified clinician, prenatal care, or the prescribing and adjustment of medication. The direct-access testing overview explains those boundaries in more detail.
There is no single best test for everyone. A1C and fasting plasma glucose are convenient first-line options, while a 75-gram oral glucose tolerance test can identify impaired glucose tolerance that the other tests miss. The right choice depends on fasting feasibility, pregnancy, symptoms, red-cell factors, medications, and the reason for testing.
It can meet a laboratory criterion, but an asymptomatic person without unequivocal hyperglycemia generally needs confirmation. A repeat A1C or a different accepted diagnostic test may be used promptly. A result should also be reviewed for red-cell or hemoglobin-related interference.1
No. A1C itself does not require fasting. If it is combined with a fasting glucose, insulin, triglyceride, or another test, follow the instructions for the entire requested set.
Fasting glucose is a point-in-time plasma measurement after at least eight hours without calories. A1C reflects longer-term glycemic exposure but also depends on red-cell biology. They can disagree, and an important mismatch deserves evaluation rather than averaging.16
The oral challenge measures how the body handles a standardized glucose load. Some people maintain an acceptable fasting value but have an excessive two-hour rise, which is why the test can identify a different group of people with impaired glucose tolerance.
No. Professional laboratory guidance does not recommend routine insulin testing for most people at risk for or living with diabetes. Assays are not standardized for a universal diagnostic cutoff, and a result often does not change management beyond established risk factors and glycemia measures.5
Both are released when the pancreas makes insulin, but injected insulin does not contain C-peptide. That makes C-peptide useful for estimating endogenous secretion in selected classification and hypoglycemia questions. Interpretation still requires concurrent glucose, kidney function, treatment, and timing.13
Not routinely. Fructosamine reflects a shorter interval and can help when A1C is unreliable, but it does not use the same standardized diabetes diagnostic thresholds. Protein turnover and albumin-related conditions can also influence it.5
No. Urine glucose depends on renal handling and does not replace plasma criteria. Urine ketones can be a warning signal, but blood beta-hydroxybutyrate and a full clinical assessment are more appropriate for suspected ketoacidosis.5
No. Gestational diabetes screening and diagnosis use pregnancy-specific protocols, glucose loads, timing, and cutoffs. Prenatal clinicians should select and interpret the pathway.14
Increased thirst and urination, hunger, fatigue, blurred vision, unexplained weight loss, slow-healing sores, or recurrent infections can occur, but type 2 diabetes may also be silent. Rapid worsening with vomiting, abdominal pain, abnormal breathing, dehydration, or confusion requires urgent care.15
About every three months is common when treatment changes or goals are not met because that interval captures a meaningful change in longer-term exposure. People who are stable and meeting goals may be assessed at least twice yearly. The care plan and clinical circumstances determine the actual schedule.17
No. A1C can miss post-challenge hyperglycemia and can be distorted by red-cell or hemoglobin factors. Symptoms, fasting glucose, an oral challenge, pregnancy status, and home or continuous glucose patterns may justify a different test.
Arrange timely clinical review. If there are no classic symptoms or crisis, expect confirmation with an accepted diagnostic test and a review of possible interference. If you are acutely ill or have crisis symptoms, seek urgent care instead of waiting for routine follow-up.
Ulta Lab Tests provides direct-access laboratory testing. Product links are included when they match the educational topic; purchasing a test is not a substitute for diagnosis, treatment, or urgent medical care.
Written by: John R. | Originally published: August 1, 2026 | Last updated: August 7, 2026
Medical note: This guide is educational. A clinician should select and interpret testing in the context of symptoms, diagnoses, medications, pregnancy status, nutrition, hydration, and prior results. Do not start, stop, or change a prescription based on this article or one laboratory result.
Blood gas testing: The article discusses blood gases only in an acute-care context. A routine direct-access product link should not be added because suspected diabetic ketoacidosis or another diabetic emergency requires urgent professional evaluation.
The random urine albumin-with-creatinine test supports calculation of the urine albumin-to-creatinine ratio, or uACR. The creatinine test provides kidney-filtration context, including eGFR when reported.
These tests do not diagnose diabetes. They may help identify anemia, altered red-blood-cell turnover, iron abnormalities, hemoglobin variants, or vitamin B12 deficiency that can affect A1C interpretation or medication monitoring.
These areas support the pillar’s sections on cardiovascular risk, diabetic kidney disease, metabolic liver health, body weight, gestational diabetes, and PCOS-related glucose regulation.
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
